GlassScriptPhysician profile
Mark W Pasmantier
NPI 1558430199
$716.35
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $75.51 · 2021: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $324.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $104.07 | 2019-2021 | |
| Clovis Oncology, INC. | $72.89 | 2019 | |
| Genentech USA, INC. | $63.31 | 2019 | |
| Celgene Corporation | $46.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $26.52 | 2019 | |
| Emd Serono, INC. | $21.01 | 2020 | |
| Janssen Biotech, INC. | $13.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pasmantier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.